Principal Financial Group Inc. lifted its position in Xencor, Inc. (NASDAQ:XNCR - Free Report) by 16.5% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 340,145 shares of the biopharmaceutical company's stock after acquiring an additional 48,229 shares during the quarter. Principal Financial Group Inc. owned 0.49% of Xencor worth $7,817,000 at the end of the most recent reporting period.
A number of other institutional investors and hedge funds also recently added to or reduced their stakes in XNCR. GAMMA Investing LLC increased its position in Xencor by 31.0% during the 4th quarter. GAMMA Investing LLC now owns 2,147 shares of the biopharmaceutical company's stock valued at $49,000 after purchasing an additional 508 shares during the period. KBC Group NV lifted its stake in shares of Xencor by 26.0% in the 4th quarter. KBC Group NV now owns 3,936 shares of the biopharmaceutical company's stock valued at $90,000 after purchasing an additional 813 shares during the period. Point72 Asia Singapore Pte. Ltd. lifted its stake in shares of Xencor by 8.5% in the 3rd quarter. Point72 Asia Singapore Pte. Ltd. now owns 12,156 shares of the biopharmaceutical company's stock valued at $244,000 after purchasing an additional 949 shares during the period. Point72 DIFC Ltd raised its position in Xencor by 10.9% during the third quarter. Point72 DIFC Ltd now owns 13,511 shares of the biopharmaceutical company's stock worth $272,000 after acquiring an additional 1,333 shares during the period. Finally, Yousif Capital Management LLC raised its position in Xencor by 10.2% during the fourth quarter. Yousif Capital Management LLC now owns 20,976 shares of the biopharmaceutical company's stock worth $482,000 after acquiring an additional 1,944 shares during the period.
Wall Street Analysts Forecast Growth
A number of equities research analysts have recently issued reports on the stock. Piper Sandler raised shares of Xencor from a "neutral" rating to an "overweight" rating and upped their target price for the stock from $20.00 to $30.00 in a report on Monday, December 2nd. BMO Capital Markets reissued an "outperform" rating and issued a $34.00 price objective (up previously from $32.00) on shares of Xencor in a report on Friday, November 8th. Wedbush reissued an "outperform" rating and issued a $38.00 price objective on shares of Xencor in a report on Thursday, November 7th. StockNews.com lowered shares of Xencor from a "hold" rating to a "sell" rating in a report on Wednesday, February 26th. Finally, Wells Fargo & Company dropped their price objective on shares of Xencor from $37.00 to $33.00 and set an "overweight" rating for the company in a report on Friday, February 28th. One equities research analyst has rated the stock with a sell rating, seven have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus price target of $34.38.
Read Our Latest Stock Analysis on Xencor
Xencor Stock Down 1.8 %
NASDAQ:XNCR traded down $0.25 during mid-day trading on Wednesday, hitting $13.90. The stock had a trading volume of 704,692 shares, compared to its average volume of 544,118. The company has a market capitalization of $979.42 million, a PE ratio of -4.34 and a beta of 0.75. Xencor, Inc. has a twelve month low of $13.64 and a twelve month high of $27.24. The company has a current ratio of 6.23, a quick ratio of 6.23 and a debt-to-equity ratio of 0.01. The stock has a 50-day simple moving average of $18.82 and a two-hundred day simple moving average of $20.63.
Xencor (NASDAQ:XNCR - Get Free Report) last announced its earnings results on Thursday, February 27th. The biopharmaceutical company reported ($0.62) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.81) by $0.19. Xencor had a negative net margin of 232.77% and a negative return on equity of 30.92%. The business had revenue of $52.79 million for the quarter, compared to analyst estimates of $17.14 million. On average, equities research analysts anticipate that Xencor, Inc. will post -3.68 EPS for the current year.
Xencor Company Profile
(
Free Report)
Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.
See Also
Before you consider Xencor, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Xencor wasn't on the list.
While Xencor currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio?
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
